Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 4
2007 2
2008 2
2009 2
2010 2
2011 6
2013 6
2014 3
2015 5
2016 1
2017 2
2018 1
2019 1
2020 3
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

37 results
Results by year
Filters applied: . Clear all
Page 1
Idursulfase in Hunter syndrome treatment.
Zareba G. Zareba G. Drugs Today (Barc). 2007 Nov;43(11):759-67. doi: 10.1358/dot.2007.43.11.1157619. Drugs Today (Barc). 2007. PMID: 18174963 Review.
Results of the randomized, double-blind, placebo-controlled phase II/III clinical trial of idursulfase demonstrated that weekly infusions of idursulfase increase walking distance and improve pulmonary function as well as reduce organ size and urinary glycosaminoglyc …
Results of the randomized, double-blind, placebo-controlled phase II/III clinical trial of idursulfase demonstrated that weekly infus …
Idursulfase: I2S, iduronato-2-sulfatase.
[No authors listed] [No authors listed] Drugs R D. 2006;7(4):254-8. doi: 10.2165/00126839-200607040-00005. Drugs R D. 2006. PMID: 16784250 Review. No abstract available.
IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome.
Kim J, Park MR, Kim DS, Lee JO, Maeng SH, Cho SY, Han Y, Ahn K, Jin DK. Kim J, et al. Allergy. 2013 Jun;68(6):796-802. doi: 10.1111/all.12155. Epub 2013 Apr 29. Allergy. 2013. PMID: 23621439
However, various adverse events can occur by the infusion of idursulfase. The purpose was to evaluate the occurrence of infusion-related allergic reactions, including anaphylaxis, to idursulfase in patients with MPS II receiving ERT and to elucidate its possi …
However, various adverse events can occur by the infusion of idursulfase. The purpose was to evaluate the occurrence of infusi …
Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial.
Okuyama T, Eto Y, Sakai N, Minami K, Yamamoto T, Sonoda H, Yamaoka M, Tachibana K, Hirato T, Sato Y. Okuyama T, et al. Mol Ther. 2019 Feb 6;27(2):456-464. doi: 10.1016/j.ymthe.2018.12.005. Epub 2018 Dec 8. Mol Ther. 2019. PMID: 30595526 Free PMC article. Clinical Trial.
Hunter syndrome (mucopolysaccharidosis II [MPS II]), a deficiency of iduronate-2-sulfatase (IDS), causes an accumulation of glycosaminoglycans, giving rise to multiple systemic and CNS symptoms. The currently available therapies, idursulfase and idursulfase beta, ar …
Hunter syndrome (mucopolysaccharidosis II [MPS II]), a deficiency of iduronate-2-sulfatase (IDS), causes an accumulation of glycosaminoglyca …
Safety and efficacy of idursulfase in the treatment of mucopolysaccharidosis II (Hunter syndrome): a post-marketing study in Japan.
Ueda K, Hokugo J. Ueda K, et al. Expert Opin Drug Saf. 2020 Jul;19(7):891-901. doi: 10.1080/14740338.2020.1751120. Epub 2020 Apr 28. Expert Opin Drug Saf. 2020. PMID: 32342708
OBJECTIVES: Enzyme replacement therapy with idursulfase has been shown to improve somatic signs and symptoms of mucopolysaccharidosis type II (MPS II). ...RESULTS: The safety and efficacy analysis populations included 145 and 143 patients, respectively. The incidence of se …
OBJECTIVES: Enzyme replacement therapy with idursulfase has been shown to improve somatic signs and symptoms of mucopolysaccharidosis …
A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II.
Muenzer J, Hendriksz CJ, Fan Z, Vijayaraghavan S, Perry V, Santra S, Solanki GA, Mascelli MA, Pan L, Wang N, Sciarappa K, Barbier AJ. Muenzer J, et al. Genet Med. 2016 Jan;18(1):73-81. doi: 10.1038/gim.2015.36. Epub 2015 Apr 2. Genet Med. 2016. PMID: 25834948 Clinical Trial.
We examined the safety of idursulfase formulated for intrathecal administration (idursulfase-IT) via intrathecal drug delivery device (IDDD). ...RESULTS: No serious adverse events related to idursulfase-IT were observed. Surgical revision/removal of th …
We examined the safety of idursulfase formulated for intrathecal administration (idursulfase-IT) via intrathecal drug delivery …
[Idursulfase desensitization in a child with Hunter syndrome (mucopolysaccharidosis II)].
Bustamante LL, Garavaglia L, Garramone EI, Amartino H, Parisi CA. Bustamante LL, et al. Arch Argent Pediatr. 2021 Feb;119(1):e41-e44. doi: 10.5546/aap.2021.e41. Arch Argent Pediatr. 2021. PMID: 33458989 Free article. Spanish.
Enzyme replacement therapy with idursulfase decreases morbidity and improves quality of life of patients with mucopolysaccharidosis ii. ...A 12-step desensitization protocol was performed without presenting adverse events. The allergological evaluation and the possi …
Enzyme replacement therapy with idursulfase decreases morbidity and improves quality of life of patients with mucopolysaccharidosis i …
Safety evaluation of chronic intrathecal administration of idursulfase-IT in cynomolgus monkeys.
Felice BR, Wright TL, Boyd RB, Butt MT, Pfeifer RW, Pan J, Ruiz JA, Heartlein MW, Calias P. Felice BR, et al. Toxicol Pathol. 2011 Aug;39(5):879-92. doi: 10.1177/0192623311409595. Epub 2011 May 31. Toxicol Pathol. 2011. PMID: 21628718
In this chronic safety study, cynomolgus monkeys were dosed weekly with IV idursulfase (0.5 mg/kg) and every four weeks with idursulfase-IT (3, 30, and 100 mg) for six months, with device and vehicle controls treated similarly (n = 6, all groups). ...The no-observed …
In this chronic safety study, cynomolgus monkeys were dosed weekly with IV idursulfase (0.5 mg/kg) and every four weeks with idurs
Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey.
Muenzer J, Beck M, Giugliani R, Suzuki Y, Tylki-Szymanska A, Valayannopoulos V, Vellodi A, Wraith JE. Muenzer J, et al. Genet Med. 2011 Feb;13(2):102-9. doi: 10.1097/GIM.0b013e318206786f. Genet Med. 2011. PMID: 21233716
PURPOSE: To use the Hunter Outcome Survey, an international database, to assess the safety and effectiveness of enzyme replacement therapy with idursulfase in patients with Hunter syndrome who started treatment before 6 years of age. ...RESULTS: The study population includ …
PURPOSE: To use the Hunter Outcome Survey, an international database, to assess the safety and effectiveness of enzyme replacement therapy w …
37 results